THE POTENTIAL OF VACCINATION TO ELIMINATE CERVICAL CANCER: ACHIEVEMENTS AND PROSPECTS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

More than 10 years of global experience with prophylactic human papillomavirus (HPV) vaccines suggest that the latter are safe and highly effective. There is convincing evidence that in countries where HPV vaccination programs are implemented, the incidence of genital warts and the incidence of cervical precancerous lesions have substantially decreased in the respective populations and in 2018 there was the first evidence for the effectiveness of vaccination against invasive HPV-associated cancers. It is predicted that cervical cancer will become an extremely rare disease over the next few decades and can be completely eradicated by the end of the century in developed countries where a high vaccination and screening coverage remains.

Full Text

Restricted Access

About the authors

Galina N. Minkina

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: minkinagn@mail.ru
Professor Delegatskaya st., 20/1, 127473, Moscow, Russia

References

  1. WHO. Human papillomavirus (HPV) and cervical cancer. 24.01.2019. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
  2. WHO. WHO Director-general calls for all countries to take action to help end the suffering caused by cervical cancer. May 19, 2018. Available at: https://www. who.int/reproductivehealth/DG_Call-to-Action.pdf
  3. Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИРЦ» Минздрава России; 2018. 250 с.
  4. Barchuk A., Bespalov A., Huhtala H., Chimed T., Laricheva I., Belyaev A. et al. Breast and cervical cancer incidence and mortality trends in Russia 1980-2013. Cancer Epidemiol. 2018; 55: 73-80.
  5. WHO. Vaccine in National Immunization Programme Update June 2019. Available at: https://www.who.int/immunization/monitoring_surveillance/en/
  6. Maver P.J., Poljak M. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review. Vaccine. 2018; 36(36): 5416-23.
  7. Department of Health and Ageing. Immunise Australia program: human papillomavirus (HPV). February 14, 2013. Available at: http://www.health.gov. au/internet/immunise/publishing.nsf/ Content/immunise-hpv
  8. Office of the Prime Minister of Australia. A new vaccine to strengthen the health of young Australians. October 8, 2017. Available at: http://parlinfo. aph.gov au/parlInfo/search/display/display.w3p;query=Id%3A%22media%2F pressrel%2F5562151%22
  9. Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National cervical screening program: guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. December 4, 2017. Available at: http://wiki.cancer. org.au/australia/Guidelines:Cervical_cancer/Screening
  10. Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2018. Sydney: Kirby Institute, UNSW Sydney; 2018. Available at: https://kirby.unsw.edu.au/report/hiv-viral-hepatitis-and-sexually-transmissible-infections-australia-annual-surveillance
  11. Victorian Cervical Cytology Registry. Statistical Report 2015. Available at: https://www.vccr.org/data-research/statistical-reports/annual-statistical-reports
  12. Steben M., Tan Thompson M., Rodier C., Mallette N., Racovitan V., DeAngelis F. et al. A review of the impact and effectiveness of the quadrivalent human papillomavirus vaccine: 10 years of clinical experience in Canada. J. Obstet. Gynaecol. Can. 2018; 40(12): 1635-45.
  13. Garland S.M., Kjaer S.K., Munoz N., Block S.L., Brown D.R., DiNubile M.J. et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin. Infect. Dis. 2016; 63(4): 519-27.
  14. Drolet M., Benard Ё., Perez N., Brisson M.; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019; Jun 26. pii: S0140-6736(19)30298-3.
  15. Luostarinen T., Apter D., Dillner J., Eriksson T., Harjula K., Natunen K. et al. Vaccination protects against invasive HPV-associated cancers. Int. J. Cancer. 2018; 142(10): 2186-7.
  16. Markowitz L.E., Dunne E.F, Saraiya M., Chesson H.W., Curtis C.R., Gee J. et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2014; 63(RR-05): 1-30.
  17. Petrosky E., Bocchini J.A. Jr, Hariri S., Chesson H., Curtis C.R., Saraiya M. et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb. Mortal. Wkly Rep. 2015; 64(11): 300-4.
  18. Guo F., Cofie L.E., Berenson A.B. Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction. Am. J. Prev. Med. 2018; 55(2): 197-204.
  19. Hall M.T., Simms K.T., Lew J.B., Smith M.A., Brotherton J.M., Saville M. et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Publ. Health. 2019; 4(1): e19-27.
  20. Simms K. Predicting declines in cervical cancer due to vaccination: the global perspective. In: Presented at EUROGIN 2018. Lisbon, Portugal. Abstr. 00570.
  21. Kjaer S.K., Nygard M., Dillner J., Brooke Marshall J., Radley D., Li M. et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. Clin. Infect. Dis. 2018; 66(3): 339-45.
  22. Kruger-Kjaer S., Nygard M., Dillner J., Munk C., Hansen B., Sigurdardottir L. Et al. In: Presented at EUROGIN 2018. Lisbon, Portugal. Abstr. 00625.
  23. WHO. Safety update of HPV vaccines. Available at: http://www.who.int/ vaccine_safety/committee/topics/hpv/June_2017/e
  24. Краснопольский В.И. и соавт. Эффективность вакцинопрофилактики ВПЧ-ассоциированных заболеваний и рака шейки матки в Московской области. Almanac of Clinical Medicine. 2015; 37: 105-110.
  25. Зароченцева Н.В., Белая Ю.М. Опыт реализации программ первичной профилактики заболеваний, вызываемых вирусом папилломы человека, в Московской области. Эпидемиология и Вакцинопрофилактика. 2017; 97(6): 59-65
  26. Белоцерковцева Л.Д. и соавт. Внедрение региональной программы вакцинации против ВПЧ-ассоциированных заболеваний в ХМАО-Югре. Педиатрическая фармакология. 2014; 11(4): 29-34
  27. Белоцерковцева Л.Д. и соавт. Репродуктивное поведение подростков и опыт профилактики ВПЧ-ассоциированных заболеваний в ХМАО-Югре. Вопросы гинекологии, акушерства и перинатологии. 2018; 17(1): 100-8

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies